The computer program forecasts individual strands of DNA building blocks (A, T, C, and G) needed to create desired patterns of gene expression in various types of cells.
Compared to existing CAR T treatments, the off-the-shelf experimental therapeutic CTX112TM may allow for quicker patient access.
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
One of the most prevalent causes of chronic liver disease in the developed world, MASLD affects about 30% of the population.
Johnson & Johnson today announced significant long-term findings from the Phase 3 QUASAR study program, demonstrating that TREMFYA® (guselkumab) delivered sustained rates of clinical remission and endoscopic improvement in adult patients with moderately to severely active ulcerative colitis (UC) through two years of continuous treatment. These compelling results underscore the […]
Amgen Inc. (NASDAQ: AMGN) announced its financial results for the first quarter ended March 31, 2025, showcasing significant revenue growth fueled by strong product volume increases across its portfolio. Financial Highlights Total Revenue: Increased 9% year-over-year to $8.1 billion, compared to $7.4 billion in Q1 2024. Product Sales: Grew 11% […]
Moderna, Inc. announced its financial results for the first quarter ending March 31, 2025, highlighting a strategic realignment towards oncology and other pipeline candidates amidst declining revenues compared to the previous year. Financial Highlights Revenue: The company reported total revenue of $108 million for Q1 2025, a decrease from $167 […]
The purpose of the duplicate, randomized, double-blind KALOS and LOGOS trials was to examine Breztri as a possible asthma medication.
Revenue reached $12.73 billion, a substantial 45% increase year-over-year, primarily fueled by strong volume growth from Mounjaro and Zepbound.
IMAAVY demonstrated a swift and significant decrease in IgG levels, a primary driver of gMG, in key adult and pediatric trials.
